Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Reply to Correspondence

Reply to correspondence on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):e218-e220. Published online February 3, 2025

DOI: https://doi.org/10.3350/cmh.2025.0070

View: 765 Download: 27

Editorial

A leap in the dark: Bariatric surgery for treatment of metabolic dysfunction-associated steatotic liver disease related cirrhosis: Editorial on “Bariatric surgery reduces long-term mortality in patients with metabolic dysfunction-associated steatotic liver disease and cirrhosis”

Jing Zeng, Jian-Gao Fan

Clin Mol Hepatol. 2025;31(2):610-614. Published online December 17, 2024

DOI: https://doi.org/10.3350/cmh.2024.1099

View: 1010 Download: 42 Web of Science: 1 Crossref: 2

Reply to Correspondence

Reply to correspondence on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: a network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):1039-1041. Published online September 24, 2024

DOI: https://doi.org/10.3350/cmh.2024.0801

View: 1317 Download: 31

Editorial

Incretin-based therapy in the management of metabolic dysfunction-associated steatotic liver disease (MASLD): one piece of the puzzle: Editorial on “Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis”

Tian-Yi Ren, Mohammed Eslam, Jian-Gao Fan

Clin Mol Hepatol. 2024;30(4):649-652. Published online July 23, 2024

DOI: https://doi.org/10.3350/cmh.2024.0558

View: 2406 Download: 102 Web of Science: 3 Crossref: 2

Review

Surveillance of the progression and assessment of treatment endpoints for nonalcoholic steatohepatitis

Yi-wen Shi, Jian-Gao Fan

Clin Mol Hepatol. 2023;29(Suppl):S228-S243. Published online December 14, 2022

DOI: https://doi.org/10.3350/cmh.2022.0401

View: 5239 Download: 127 Web of Science: 4 Crossref: 4

Editorial

Does nonalcoholic fatty liver disease predispose patients to carotid arteriosclerosis and ischemic stroke?

Qian Jin, Rui-Xu Yang, Jian-Gao Fan

Clin Mol Hepatol. 2022;28(3):473-477. Published online June 22, 2022

DOI: https://doi.org/10.3350/cmh.2022.0155

View: 4935 Download: 111 Web of Science: 2 Crossref: 2

Probiotics for treatment of nonalcoholic fatty liver disease: It is worth a try

Tian-Yi Ren, Xiao-Yan Li, Jian-Gao Fan

Clin Mol Hepatol. 2021;27(1):83-86. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0298

View: 6198 Download: 172 Web of Science: 1 Crossref: 1

Letter to the Editor

What is new in the 2024 Chinese guidelines for fatty liver disease?

Rui-Xu Yang, Vincent Wai-Sun Wong, Jian-Gao Fan

Received December 27, 2024 Accepted January 18, 2025

DOI: https://doi.org/10.3350/cmh.2024.1165 [Accepted]

View: 530 Download: 52

1 |

Viewed By 11442	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 7184	MAFLD: How is it different from NAFLD?
Viewed By 5478	Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Viewed By 5134	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 4579	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma

Cited By 349	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 328	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 219	MAFLD: How is it different from NAFLD?
Cited By 113	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 110	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search